Transcode Therapeutics (RNAZ) Other Non Operating Income (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Other Non Operating Income came in at -$21108.0 in Q1 2026, up 22.36% YoY from -$17250.3 in Q1 2025, and down 295.35% on a QoQ basis from -$5339.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Other Non Operating Income (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 5 years of Other Non Operating Income data on file, last reported at -$21108.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 22.36% year-over-year to -$21108.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$105985.0 (down 266.72% YoY) and the FY2025 annual result came in at -$112065.0, down 96.39% from the prior year.
- Other Non Operating Income slipped to -$21108.0 in Q1 2026, from -$5339.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $228196.0 in Q4 2024 to a low of -$157315.0 in Q3 2024.
- A 3-year average of -$21137.2 and a median of -$32051.0 in 2025 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 79.63% in 2025, down 102.34% in 2025.
- Tracing RNAZ's Other Non Operating Income over 3 years: stood at $228196.0 in 2024, then slumped by 102.34% to -$5339.0 in 2025, then tumbled by 295.35% to -$21108.0 in 2026.
- The last three Other Non Operating Income figures came in at -$21108.0 (Q1 2026), -$5339.0 (Q4 2025), and -$32051.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21,108.00 |
| Dec 31, 2025 | -5,339.00 |
| Sep 30, 2025 | -32,051.00 |
| Jun 30, 2025 | -47,487.00 |
| Mar 31, 2025 | -27,188.00 |
| Dec 31, 2024 | 228,196.00 |
| Sep 30, 2024 | -157,315.00 |
| Jun 30, 2024 | -72,594.00 |
| Mar 31, 2024 | -55,349.00 |
| Jun 30, 2021 | 3.07 Mn |
| Dec 31, 2020 | -368,000.00 |
| Sep 30, 2020 | -840,000.00 |